EM-T3Therapeutics and Clinical Risk Management2019-11-01第 Volume 15 卷,1325-1332开放获取
Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified